@article{article_910260, title={Use of Sodium Glucose Co-Transporter 2 Inhibitor (SGLT2i) in Geriatric Population}, journal={Turkish Journal of Diabetes and Obesity}, volume={5}, pages={158–164}, year={2021}, DOI={10.25048/tudod.910260}, author={Taşkaldıran, Işılay and Kuşkonmaz, Şerife and Çulha, Cavit}, keywords={Elderly, Diabetes mellitus, SGLT2 inhibitor, Elderly, Diabetes mellitus, SGLT2 inhibitor}, abstract={<p>Aim: Diabetes treatment and follow-up is more difficult and sensitive in the elderly. Sodium glucose co-transporter type 2 (SGLT2) <br />inhibitors are newly developed antidiabetic agents. In the geriatric age group, the use of SGLT2 inhibitors may be riskier in terms of side <br />effects. We planned to evaluate the effect and tolerability of using SGLT2 inhibitors in geriatric patients. <br />Material and Methods: Patients over 65 years of age with a diagnosis of type 2 DM who were started on empagliflozin or dapagliflozin <br />in our center were included in the study. A total of 52 patients were included in the study. The study was designed as a retrospective file <br />scan. Before and after SGLT2 inhibitor treatment, biochemical data, drug-related side effects and drug withdrawal information were <br />recorded. <br />Results: A statistically significant decrease was observed in the fasting blood glucose (FBG), postprandial blood glucose (PPBG), and <br />HbA1c values of the patients after the SGLT2 inhibitor was started. While the urea and creatinine values of the patients increased after <br />the treatment, a decrease was observed in the eGFR value. After treatment, a decrease in albumin/creatinine ratio in spot urine and an <br />increase in hemoglobin and hematocrit values were observed. No complaints were reported in 31 patients (59.6%) and no side effects <br />were detected. Side effects associated with SGLT2 inhibitor were observed in 21 patients (40.3%). In total, treatment was continued in 41 <br />patients (78.8%) out of 52 patients, while treatment was discontinued in 11 patients (21.2%). <br />Conclusion: In type 2 DM population over 65 years of age, glycemic control with SGLT 2 inhibitor treatment is successful, side effects <br />and drug withdrawal rates are within acceptable limits. <br /> </p>}, number={2}, publisher={Zonguldak Bulent Ecevit University}